Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Szukaj Study Connect

Not Yet Recruiting

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants - CA127-1072

Zaktualizowano: 8 lipiec, 2024   |   ClinicalTrials.gov

Wydruk podsumowania

BIERZESZ POD UWAGĘ TO BADANIE?
Wydrukuj tę stronę i przewodnik po badaniu, aby pomóc sobie w rozmowie z lekarzem.
Skorzystaj z Przewodnika po badaniu, aby dowiedzieć się o procesie badań klinicznych. Zapoznaj się z kluczowymi czynnikami, które należy wziąć pod uwagę przed podjęciem decyzji i zanotuj pytania, aby zadać je personelowi medycznemu.

Szczegóły badania

  • Phase 1

    Etap

  • Płeć

  • 18-55

    Zakres wieku

  • 1

    Lokalizacje

  • Not Yet Recruiting

Opcje leczenia

Grupy badania
PRZYPISANA INTERWENCJA
Experimental: Part 1
Drug: Repotrectinib, Voriconazole
Experimental: Part 2
Drug: Repotrectinib, Quinidine

Kluczowe kryteria kwalifikacyjne

Inclusion Criteria - Healthy male and female individual(s) not of childbearing potential (INOCBP) participants of any race or ethnicity, as determined by no clinically significant findings in medical history, physical examination, 12-lead ECG, or vital signs as determined by the investigator or designee. - Potassium, magnesium, and calcium at or above the lower limit of normal. For other clinical laboratory parameters, no clinically significant findings as determined by the investigator or designee. - Must have a body mass index between 18 and 30 kg/m2 (inclusive) and body weight ≥ 50 kg at the time of signing the ICF. Exclusion Criteria - History of clinically significant acute or chronic medical illness, such as endocrine, gastrointestinal (GI), cardiovascular, peripheral vascular, hematological, hepatic, immunological, renal, respiratory, neoplastic, or genitourinary abnormalities/diseases as determined by the investigator or designee. - History of GI disease or surgery that could possibly affect drug absorption, distribution, metabolism, and excretion (ADME) (eg, bariatric procedure, cholecystectomy). Uncomplicated appendectomy and hernia repair are acceptable. - Gilbert's syndrome. - Other protocol-defined Inclusion/Exclusion criteria apply.